How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

22,076 results for

osteoporosis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Management of osteoporosis and the prevention of fragility fractures

Management of osteoporosis and the prevention of fragility fractures Management of osteoporosis and the prevention of fragility fractures A national clinical guideline First published March 2015 Revised edition published June 2020 SIGN142Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta (...) used by Scottish Intercollegiate Guidelines Network to produce clinical guidelines. The accreditation term is valid until 30 June 2020 and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2019 edition (https://www.sign.ac.uk/assets/sign50_2019.pdf). More information on accreditation can be viewed at www.nice.org.uk/accreditationScottish Intercollegiate Guidelines Network Management of osteoporosis and the prevention of fragility

2020 SIGN

2. Denosumab (Prolia) and steroid-induced osteoporosis

Denosumab (Prolia) and steroid-induced osteoporosis Prescrire IN ENGLISH - Spotlight ''Denosumab (Prolia°) and steroid-induced osteoporosis'', 1 April 2020 {1} {1} {1} | | > > > Denosumab (Prolia°) and steroid-induced osteoporosis Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the April issue of Prescrire International: Denosumab (Prolia (...) °) and steroid-induced osteoporosis FREE DOWNLOAD Denosumab (Prolia°) has an unfavourable harm-benefit balance in the prevention of osteoporotic fractures. It has also been authorised in the prevention of osteoporosis induced by prolonged corticosteroid therapy. How do Prescrire's editors rate denosumab in this situation? Full text available for free download. Prescrire's rating NOT ACCEPTABLE Denosumab has not been shown to prevent clinical fractures, but it has many adverse effects that can be severe

2020 Prescrire

3. Teriparatide (Osnuvo) - osteoporosis

Teriparatide (Osnuvo) - osteoporosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

4. Osteoporosis

Osteoporosis Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

5. Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines

Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines | CADTH.ca Find the information you need Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Last updated: August 22, 2019 Project Number (...) : RA1059-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical evidence for varying treatment duration and courses of bisphosphonates for osteoporosis? What are the evidence-based guidelines regarding length of treatment with bisphosphonates for osteoporosis? Key Message One health technology assessment, six systematic reviews (one with meta-analyses), three randomized controlled trials, and five non-randomized studies were identified

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Full Text available with Trip Pro

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Navbar Search Filter Mobile (...) Microsite Search Term search filter search input Article Navigation Close mobile search navigation Article Navigation March 2020 Article Contents Article Navigation Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Dolores Shoback Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, Department of Medicine , San Francisco, California Department of Medicine, University of California San Francisco , San Francisco, California Search

2020 The Endocrine Society

7. Romosozumab (Evenity) - treatment of osteoporosis in postmenopausal women at high risk for fracture

Romosozumab (Evenity) - treatment of osteoporosis in postmenopausal women at high risk for fracture Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

8. Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture

Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture Drug Approval Package: Evenity U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Evenity Company: Amgen Inc. Application Number: 761062 Approval Date: 04/09/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2019 FDA - Drug Approval Package

9. Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women

Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women | CADTH.ca Find the information you need Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Last updated: October 11, 2019 Project Number: HE0023-000 Product Line: Technology Review Research Type: Drug Result type: Report Expected (...) Completion Date: December 20, 2019 Osteoporosis is a systemic skeletal disease characterized by a loss of bone mass and an increased risk of fragility fractures. Osteoporosis is highly prevalent, affecting an estimated 1.5 million Canadians over 40 years of age. Fractures associated with osteoporosis commonly occur in vertebral sites, but also occur in non-vertebral sites. They are associated with significant costs, diminished quality of life, and mortality, as well as an increased risk of future

2019 CADTH - Technology Review

10. Romosozymab (Evenity) - Osteoporosis

Romosozymab (Evenity) - Osteoporosis Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing

2019 Health Canada - drugs and medical devices

11. AACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

AACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 26 (Suppl 1) May 2020 1 Copyright © 2020 AACE Clinical Practice Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE Pauline M. Camacho, MD, FACE 1 ; Steven M. Petak, MD, JD, FACP , FCLM, MACE, CCD 2 ; Neil Binkley, MD 3 ; Dima L (...) , 2020 From the 1 Guideline Task Force Co-Chair, Professor of Medicine, Director, Loyola University Osteoporosis and Metabolic Bone Disease Center, Maywood, Illinois, 2 Guideline Task Force Co-Chair, Associate Clinical Professor, Weill-Cornell Medical College, Division Head and Service Chief, Endocrinology, Houston Methodist Hospital, Charles and Anne Duncan Centennial Clinical Academic Scholar in Endocrinology, Houston, Texas, 3 Professor of Medicine, Divisions of Endocrinology and Geriatrics

2020 American Association of Clinical Endocrinologists

12. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: February 2019 Last updated: October 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female sex, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

2018 BMJ Best Practice

13. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: February 2019 Last updated: October 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female sex, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

2018 BMJ Best Practice

14. Bindex for people with suspected osteoporosis

Bindex for people with suspected osteoporosis Binde Bindex for in x for inv vestigating suspected osteoporosis estigating suspected osteoporosis Medtech innovation briefing Published: 31 May 2017 nice.org.uk/guidance/mib106 pathways Summary Summary The technology technology described in this briefing is Bindex, a portable pulse-echo ultrasound device used to help make decisions on the investigation and treatment of osteoporosis. The inno innovativ vative aspects e aspects are that it is pocket (...) sized and can be connected to and used with any laptop or desktop computer's USB socket. Unlike other quantitative ultrasound that measures sound speed and attenuation in the heel, Bindex makes measurements of the tibia applying thresholds of 90% sensitivity and specificity compared with axial dual-energy X-ray absorptiometry (DXA), to help with decisions on further tests and treatment for osteoporosis. The intended place in ther place in therap apy y would be to use Bindex alongside current

2017 National Institute for Health and Clinical Excellence - Advice

15. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice. Full Text available with Trip Pro

Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice. Among Australians aged 50 and over, an estimated 1 in 4 men and 2 in 5 women will experience a minimal trauma fracture during their remaining lifetime. Effective fracture prevention is hindered by substantial undertreatment, even of patients who clearly warrant pharmacological therapy. Poor adherence to osteoporosis treatment is also a leading cause of repeat (...) fractures and hospitalisation. The aim of this study was to identify current osteoporosis treatment patterns and gaps in practice in Australia, using general practice data, and to explore general practitioners' (GPs') attitudes to osteoporosis treatment and their views on patient factors affecting osteoporosis management.The study was conducted in two phases. Phase 1 was a longitudinal retrospective cohort study which utilised data from MedicineInsight - a national general practice data program

2020 BMC Family Practice

16. A correlative studies between osteoporosis and blood cell composition: Implications for auxiliary diagnosis of osteoporosis. Full Text available with Trip Pro

A correlative studies between osteoporosis and blood cell composition: Implications for auxiliary diagnosis of osteoporosis. Osteoporosis is defined as a metabolic skeletal disease characterized by a decrease of the bone mass per unit volume, caused by a variety of reasons. Increasing evidence indicate that the host inflammatory response was correlated with the occurrence and development of osteoporosis, and it has been recognized that T lymphocytes and B lymphocytes play a critical role (...) in pathogenesis of inflammatory bone disease. Between January 2018 and December 2018, retrospective analysis of 487 patients (exclusion of patients with recent infections and hematologic disorders whose leukocyte counts or classifications are markedly abnormal) who underwent bone mineral density (BMD) examinations in Huzhou Central Hospital. The patients were divided into normal bone density group, osteopenia group, and osteoporosis group according to the T score of BMD in the left femoral neck, respectively

2020 Medicine

17. Osteoporosis

Osteoporosis Top results for osteoporosis - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for osteoporosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

18. Bisphosphonates for treating osteoporosis

Bisphosphonates for treating osteoporosis Bisphosphonates for treating Bisphosphonates for treating osteoporosis osteoporosis T echnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents 1 Recommendations 4 2 The technologies 7 3 Committee discussion 9 Nature of the condition 9 Clinical management of the condition 9 Assessing

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>